Two sensitive, specific, and selective stability-indicating chromatographic methods were developed for the determination of cyclobenzaprine HCl (CZ) and asenapine maleate (AS) in pure forms, in the presence of their degradation products and in their pharmaceutical formulations. The first method was an isocratic reversed-phase high-performance liquid chromatography (RP-HPLC). Analysis was performed on cyano column using a mobile phase consisting of acetonitrile–(0.05 m) potassium dihydrogen phosphate buffer (pH 3 ± 0.1) (70:30, v/v) with a flow rate of 1.5 mL min−1 and ultraviolet (UV) detection at 290 nm for the determination of CZ, and methanol–(0.05 m) potassium dihydrogen phosphate buffer (pH 6 ± 0.1) (70:30, v/v) with a flow rate of 1.5 mL min−1 and UV detection at 220 nm for the determination of AS. The second method was thin-layer chromatography (TLC), using silica gel 60 F254 plates and toluene–methanol–chloroform-ammonia solution 33% (5:3:6:0.1, by volume) as the mobile phase for the two drugs. The spots were scanned densitometrically at 290 and 220 nm for the determination of CZ and AS, respectively. The methods were validated according to the International Conference on Harmonization (ICH) guidelines, and the acceptance criteria for linearity, accuracy, precision, specificity, and system suitability were met in all cases. The linearity ranges were 2.5–25 μg mL−1 for the RP-HPLC method and 5–50 μg band−1 for the TLC method for both drugs. The limits of detection for the RP-HPLC method were 0.250 and 0.578 for CZ and AS, respectively, while the limits of quantification were 0.758 and 1.572 for CZ and AS, respectively. The limits of detection for the TLC method were 1.355 and 1.284 for CZ and AS, respectively, while the limits of quantification were 4.472 and 3.891 for CZ and AS, respectively. The results were compared statistically at a 95% confidence level with the reported methods. There were no significant differences between the mean percentage recoveries and the precisions of the two methods.
A.Brayfield (ed.), Martindale: The Complete Drug Reference, 3rd edn., Pharmaceutical Press, London, 2002, p. 1328.
A.Brayfield (ed.), Martindale: The Complete Drug Reference, 3rd edn., Pharmaceutical Press, London, 2002, p. 1328.)| false